8-K: Bio-Path Holdings Presents Promising Phase 2 AML Data at European Hematology Congress

Bio-Path Holdings presented positive interim results from its Phase 2 study of prexigebersen in combination with other drugs for acute myeloid leukemia (AML), showing significant clinical improvement and a tolerable safety profile.

Summary

• Bio-Path Holdings presented interim data from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML) at the European Hematology Association (EHA) Congress.
• The study included two cohorts: newly diagnosed AML patients and relapsed/refractory AML patients.
• In the newly diagnosed cohort, 20 evaluable patients with a median age of 75 years were treated, with 75% achieving complete remission (CR), CR with partial recovery of peripheral blood counts (CRh), or CR with incomplete hematologic recovery (CRi).
• In the relapsed/refractory cohort, 23 evaluable patients with a median age of 63 years were treated, with 55% achieving CR/CRi/CRh.
• Adverse events were consistent with those expected with the combination therapy and AML, including fatigue, anemia, and neutropenia.
• The company plans to continue enrollment, aiming for up to 98 and 54 evaluable patients for Cohorts 1 and 2, respectively.

Sentiment

Score: 8

Explanation: The document presents very positive interim results from a Phase 2 clinical trial, indicating a potential breakthrough in AML treatment. The high remission rates and manageable safety profile are encouraging, although the need for additional capital is a risk.

Positives

• The study demonstrated significant clinical improvement in both newly diagnosed and relapsed/refractory AML patients.
• The combination therapy showed a high rate of complete remission or complete remission with incomplete or partial hematologic recovery.
• Prexigebersen was well-tolerated, with adverse events consistent with the expected side effects of the combination therapy.
• The encore presentation at the European Hematology Association Congress is an important step towards educating global oncology leaders about the potential of prexigebersen.

Negatives

• The study reported common adverse events such as fatigue (72%), anemia (60%), and neutropenia (49%).
• Severe adverse events included febrile neutropenia (26%) and sepsis (5%).

Risks

• The company's ability to raise additional capital is crucial for continued operations and clinical development.
• The success of clinical development is not guaranteed, and results from later-stage trials may differ from earlier-stage trials.
• There are risks associated with the timing of enrollment and release of data in clinical studies.
• The company faces risks related to the maintenance of intellectual property rights and the issuance of patents.
• Global pandemics, such as COVID-19, can impact the company's operations and clinical trials.

Future Outlook

Bio-Path expects to continue enrollment of up to 98 and 54 evaluable patients for Cohorts 1 and 2, respectively.

Management Comments

• Peter Nielsen, Chief Executive Officer of Bio-Path, stated that it was a pleasure to present the data to European oncologists.
• Peter Nielsen also noted that the encore presentation is an important step towards educating global oncology leaders on the benefits of prexigebersen.

Industry Context

The presentation of positive Phase 2 data at a major European hematology conference highlights the potential of Bio-Path's technology in the competitive landscape of cancer therapeutics, particularly in the treatment of AML, where new therapeutic options are needed.

Comparison to Industry Standards

• The complete remission rates of 75% in newly diagnosed AML and 55% in relapsed/refractory AML patients are promising when compared to standard frontline therapies, which often have lower remission rates, particularly in older and high-risk patients.
• While specific benchmarks for combination therapies like prexigebersen, decitabine, and venetoclax are still emerging, these results suggest a potential improvement over existing treatments.
• Companies like AbbVie and Genentech, which market venetoclax, have shown success in AML treatment, but Bio-Path's approach with prexigebersen offers a novel mechanism of action that could address unmet needs.
• The tolerability profile of the combination, while showing expected side effects, appears manageable, which is crucial for patient compliance and treatment success.

Stakeholder Impact

• Shareholders may view the positive clinical trial results favorably, potentially increasing the company's stock value.
• Patients with AML may benefit from a new treatment option with promising efficacy.
• Employees of Bio-Path may be motivated by the positive results and the potential for the company's technology to make a significant impact.
• The medical community may be interested in further research and development of prexigebersen.

Next Steps

• Bio-Path will continue enrollment in the Phase 2 study to reach the target of 98 and 54 evaluable patients for Cohorts 1 and 2, respectively.
• The company will continue to educate global oncology leaders on the benefits of prexigebersen.

Key Dates

Keywords

Acute Myeloid Leukemia, AML, Prexigebersen, BP1001, Decitabine, Venetoclax, Phase 2 Study, Hematology, Oncology, Clinical Trial, Cancer Treatment, DNAbilize, Antisense Technology